ScienceMed®

Impacto da obesidade sobre os desfechos clínicos e o efeito do tratamento da ablação do cateter na fibrilação atrial: insights do CABANA

Cardiologia
Imagem de arquivo, ilustrativa — não é do estudo. Músculo cardíaco em corte transversal, ao microscópio óptico. Berkshire Community College Bioscience Image Library · CC0 · Wikimedia Commons

Ensaio clínico randomizadoNível 2 · Nova evidênciaEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology1 out 20261 citações

Salvar

Resumo original em inglês

O que aconteceu

Obesity and atrial fibrillation (AF) are global epidemics, often co-existing and compounding cardiovascular risk. While catheter ablation has emerged as an effective strategy for rhythm control in symptomatic AF, it remains unclear whether obesity modifies its benefit. This post hoc analysis of the CABANA trial investigates the influence of baseline obesity on clinical outcomes after catheter ablation vs. drug therapy in AF patients. A total of 2170 CABANA participants with available body mass index (BMI) were included. Obesity was defined by BMI ≥ 30 kg/m2, and Class II obesity by BMI ≥ 35 kg/m2. Adverse outcomes, AF recurrence, and functional status were analysed using Cox, mixed-effects, and generalized estimating equation models, assessing treatment-by-obesity interactions. Obese patients exhibited higher comorbidity burden, worse baseline functional status, and more persistent AF compared to non-obese counterparts. Higher BMI was associated with increased cardiovascular hospitalization and a higher New York Heart Association functional class. Catheter ablation significantly reduced the risk of AF recurrence and improved symptom burden and functional capacity, irrespective of obesity status. No significant interaction was found between BMI and treatment effect on the primary composite endpoint of cardiovascular hospitalization or all-cause mortality. However, patients with Class II obesity or higher had worse absolute outcomes despite similar relative benefits from ablation. While obesity is associated with worse baseline status and outcomes, it was not shown to significantly alter the relative effectiveness of AF ablation compared to drug therapy. These findings support a multifaceted approach integrating rhythm control with upstream interventions targeting obesity-related atrial remodelling and comorbidity management.

Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.

O estudo original

Impact of obesity on clinical outcomes and the treatment effect of catheter ablation in atrial fibrillation: insights from CABANA

Jonas Erzeel, Sebastiaan Dhont, Marnicq van Es, Michiel De Wever, Evelyne Meekers, Hugo Van Herendael, Dieter Nuyens, Maximo Rivero-Ayerza, Laurent Pison, Wilfried Mullens et al.

Descritores MeSH

  • Catheter Ablation
  • Anti-Arrhythmia Agents
  • Atrial Fibrillation
  • Obesity
  • Humans
  • Male
  • Middle Aged
  • Aged
  • Recurrence
  • Risk Factors

Veja também